Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $4.0 billion.

  • BeOne Medicines' Cash & Current Investments rose 4940.67% to $4.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 billion, marking a year-over-year increase of 4940.67%. This contributed to the annual value of $2.6 billion for FY2024, which is 1723.13% down from last year.
  • Per BeOne Medicines' latest filing, its Cash & Current Investments stood at $4.0 billion for Q3 2025, which was up 4940.67% from $2.8 billion recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Cash & Current Investments ranged from a high of $6.6 billion in Q4 2021 and a low of $2.5 billion during Q1 2025
  • Over the past 5 years, BeOne Medicines' median Cash & Current Investments value was $3.8 billion (recorded in 2023), while the average stood at $3.9 billion.
  • In the last 5 years, BeOne Medicines' Cash & Current Investments plummeted by 3862.71% in 2023 and then soared by 4940.67% in 2025.
  • Over the past 5 years, BeOne Medicines' Cash & Current Investments (Quarter) stood at $6.6 billion in 2021, then tumbled by 31.47% to $4.5 billion in 2022, then fell by 30.0% to $3.2 billion in 2023, then dropped by 17.23% to $2.6 billion in 2024, then soared by 53.64% to $4.0 billion in 2025.
  • Its Cash & Current Investments stands at $4.0 billion for Q3 2025, versus $2.8 billion for Q2 2025 and $2.5 billion for Q1 2025.